NASDAQ:ANIX Anixa Biosciences (ANIX) Stock Price, News & Analysis → Don't Pay a Dime for Marc Lichtenfeld's Top AI Picks (From The Oxford Club) (Ad) Free ANIX Stock Alerts $2.61 -0.11 (-4.04%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$2.61▼$2.7550-Day Range$2.36▼$3.2552-Week Range$2.21▼$5.13Volume42,430 shsAverage Volume125,634 shsMarket Capitalization$83.55 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Anixa Biosciences alerts: Email Address Anixa Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside164.2% Upside$7.00 Price TargetShort InterestHealthy1.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.92Based on 17 Articles This WeekInsider TradingAcquiring Shares$286,391 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.43) to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.47 out of 5 starsMedical Sector460th out of 917 stocksPharmaceutical Preparations Industry211th out of 431 stocks 3.5 Analyst's Opinion Consensus RatingAnixa Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnixa Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Anixa Biosciences' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.80% of the float of Anixa Biosciences has been sold short.Short Interest Ratio / Days to CoverAnixa Biosciences has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Anixa Biosciences has recently decreased by 1.05%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAnixa Biosciences does not currently pay a dividend.Dividend GrowthAnixa Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANIX. Previous Next 3.3 News and Social Media Coverage News SentimentAnixa Biosciences has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Anixa Biosciences this week, compared to 2 articles on an average week.Search Interest14 people have searched for ANIX on MarketBeat in the last 30 days. This is an increase of 180% compared to the previous 30 days.MarketBeat Follows11 people have added Anixa Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 175% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anixa Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $286,391.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders22.60% of the stock of Anixa Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 29.13% of the stock of Anixa Biosciences is held by institutions.Read more about Anixa Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Anixa Biosciences are expected to decrease in the coming year, from ($0.43) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anixa Biosciences is -7.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anixa Biosciences is -7.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnixa Biosciences has a P/B Ratio of 3.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Anixa Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressDiscover How to Turn $10,000 into $1 MillionToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.That will slam shut June 25. About Anixa Biosciences Stock (NASDAQ:ANIX)Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Read More ANIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANIX Stock News HeadlinesJune 11 at 5:13 AM | insidertrades.comInsider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Purchases 10,738 Shares of StockJune 8, 2024 | insidertrades.comInsider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) CFO Acquires 6,250 Shares of StockJune 12 at 6:56 AM | americanbankingnews.comHC Wainwright Equities Analysts Boost Earnings Estimates for Anixa Biosciences, Inc. (NASDAQ:ANIX)June 12 at 5:18 AM | americanbankingnews.comLewis H. Titterton, Jr. Buys 10,738 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) StockJune 11 at 3:36 AM | americanbankingnews.comAnixa Biosciences (NASDAQ:ANIX) Price Target Lowered to $7.00 at HC WainwrightJune 10, 2024 | americanbankingnews.comInsider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) CFO Buys 6,250 Shares of StockJune 10, 2024 | americanbankingnews.comAnixa Biosciences, Inc. (NASDAQ:ANIX) CEO Purchases $60,250.00 in StockJune 7, 2024 | americanbankingnews.comAnixa Biosciences (NASDAQ:ANIX) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPSJune 7, 2024 | americanbankingnews.comAnixa Biosciences (NASDAQ:ANIX) Announces Earnings ResultsMay 28, 2024 | investorplace.com7 Penny Biotech Stocks to Triple Your InvestmentMay 21, 2024 | finanznachrichten.deAnixa Biosciences, Inc.: Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical TrialMay 21, 2024 | prnewswire.comAnixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical TrialMay 8, 2024 | finanznachrichten.deAnixa Biosciences, Inc.: Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer VaccinesMay 8, 2024 | msn.comAnixa Biosciences enters JV with Cleveland Clinic for additional cancer vaccinesMay 8, 2024 | markets.businessinsider.comAnixa Inks Joint Development Agreement With Cleveland Clinic To Develop Novel Cancer VaccinesMay 8, 2024 | prnewswire.comAnixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer VaccinesMay 6, 2024 | prnewswire.comAnixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay JunejaApril 30, 2024 | prnewswire.comAnixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024April 18, 2024 | finance.yahoo.comAnixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory BoardMarch 16, 2024 | finance.yahoo.comANIX Apr 2024 2.500 putMarch 16, 2024 | finance.yahoo.comANIX Apr 2024 7.500 callMarch 14, 2024 | prnewswire.comAnixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested PartiesMarch 12, 2024 | benzinga.comRecap: Anixa Biosciences Q1 EarningsMarch 11, 2024 | prnewswire.comAnixa Biosciences Announces Presentation at 24th Annual World Vaccine CongressFebruary 22, 2024 | benzinga.comAnixa Biosciences Stock (NASDAQ:ANIX) Insider TradesSee More Headlines Receive ANIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/04/2024Today6/14/2024Next Earnings (Estimated)9/04/2024Fiscal Year End10/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ANIX CUSIPN/A CIK715446 Webwww.anixa.com Phone(408) 708-9808Fax631-549-5974Employees4Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+157.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,810,000.00 Net MarginsN/A Pretax Margin-5,174.29% Return on Equity-49.27% Return on Assets-45.55% Debt Debt-to-Equity RatioN/A Current Ratio14.40 Quick Ratio14.40 Sales & Book Value Annual Sales$210,000.00 Price / Sales414.61 Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book3.83Miscellaneous Outstanding Shares32,010,000Free Float24,773,000Market Cap$87.07 million OptionableOptionable Beta0.84 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Amit Kumar Ph.D. (Age 60)CEO, Chairman & Co-Chair of CBAB Comp: $1.29MMr. Michael J. Catelani CPA (Age 57)MBA, President, COO, CFO & Corporate Secretary Comp: $788.83kMr. John Roop (Age 74)Senior Vice President of Engineering Comp: $275kDr. Pamela D. Garzone Ph.D. (Age 69)Chief Development Officer & Chair Breast Cancer Clinical Advisory Board Key CompetitorsEnzo BiochemNYSE:ENZPsychemedicsNASDAQ:PMDEmergent BioSolutionsNYSE:EBSSilverback TherapeuticsNASDAQ:SBTXAlto NeuroscienceNYSE:ANROView All CompetitorsInsiders & InstitutionsLewis H Titterton JrBought 405 shares on 6/13/2024Total: $1,093.50 ($2.70/share)Lewis H Titterton JrBought 330 shares on 6/10/2024Total: $858.00 ($2.60/share)Lewis H Titterton JrBought 10,738 shares on 6/7/2024Total: $27,059.76 ($2.52/share)Amit KumarBought 25,000 shares on 6/7/2024Total: $60,250.00 ($2.41/share)Michael CatelaniBought 6,250 shares on 6/7/2024Total: $15,000.00 ($2.40/share)View All Insider TransactionsView All Institutional Transactions ANIX Stock Analysis - Frequently Asked Questions Should I buy or sell Anixa Biosciences stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anixa Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANIX shares. View ANIX analyst ratings or view top-rated stocks. What is Anixa Biosciences' stock price target for 2024? 1 equities research analysts have issued twelve-month price targets for Anixa Biosciences' stock. Their ANIX share price targets range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 164.2% from the stock's current price. View analysts price targets for ANIX or view top-rated stocks among Wall Street analysts. How have ANIX shares performed in 2024? Anixa Biosciences' stock was trading at $3.88 at the beginning of the year. Since then, ANIX shares have decreased by 31.7% and is now trading at $2.65. View the best growth stocks for 2024 here. When is Anixa Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, September 4th 2024. View our ANIX earnings forecast. How were Anixa Biosciences' earnings last quarter? Anixa Biosciences, Inc. (NASDAQ:ANIX) announced its quarterly earnings results on Tuesday, June, 4th. The company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. What other stocks do shareholders of Anixa Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anixa Biosciences investors own include Cronos Group (CRON), Innovative Industrial Properties (IIPR), Roku (ROKU), Ally Financial (ALLY), Albireo Pharma (ALBO), Air Lease (AL), Akoustis Technologies (AKTS), Akero Therapeutics (AKRO), Aimmune Therapeutics (AIMT) and Advanced Emissions Solutions (ADES). Who are Anixa Biosciences' major shareholders? Anixa Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.05%), Simplicity Wealth LLC (0.04%), Staley Capital Advisers Inc. (0.03%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Amit Kumar, Arnold M Baskies, Lewis H Titterton Jr and Michael Catelani. View institutional ownership trends. How do I buy shares of Anixa Biosciences? Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ANIX) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages...Weiss Ratings | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
